iral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days